Stocks News

LAST PRICE
91.5600
TODAY'S CHANGE (%)
Trending Down-4.2800 (-4.4658%)

Bid / Lots
89.7700/ 1
Ask / Lots
91.6000/ 3
Open / Previous Close
96.3600 / 95.8400
Day Range
Low 90.5100
High 96.4714
52 Week Range
Low 55.0200
High 98.4000
Volume
672,767
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Sep 20, 2024
- DJ Axsome Therapeutics Price Target Maintained With a $107.00/Share by Cantor Fitzgerald, from 1:33PM ET on Friday Sep 20, 2024 by Dow Jones
  1:33PM ET on Friday Sep 20, 2024 by Dow Jones
  Companies Mentioned: AXSM
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/AXSM/analyst-ratings
  
  (END) Dow Jones Newswires
  
  September 20, 2024 13:33 ET (17:33 GMT)
Sep 16, 2024
- DJ Axsome Therapeutics Price Target Maintained With a $107.00/Share by Cantor Fitzgerald, from 11:34AM ET on Monday Sep 16, 2024 by Dow Jones
  11:34AM ET on Monday Sep 16, 2024 by Dow Jones
  Companies Mentioned: AXSM
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/AXSM/analyst-ratings
  
  (END) Dow Jones Newswires
  
  September 16, 2024 11:34 ET (15:34 GMT)
Sep 12, 2024
- Axsome Therapeutics Insider Sold Shares Worth $1,005,871, According to a Recent SEC Filing, from 3:14AM ET on Thursday Sep 12, 2024 by MT Newswires
  3:14AM ET on Thursday Sep 12, 2024 by MT Newswires
  Companies Mentioned: AXSM
  03:14 AM EDT, 09/12/2024 (MT Newswires) -- Mark E Saad, Director, on September 11, 2024, sold 11,016 shares in Axsome Therapeutics (AXSM) for $1,005,871. Following the Form 4 filing with the SEC, Saad has control over a total of 10,302 shares of the...
Sep 9, 2024
- DJ Axsome Therapeutics Price Target Maintained With a $107.00/Share by Cantor Fitzgerald, from 11:31AM ET on Monday Sep 09, 2024 by Dow Jones
  11:31AM ET on Monday Sep 09, 2024 by Dow Jones
  Companies Mentioned: AXSM
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/AXSM/analyst-ratings
  
  (END) Dow Jones Newswires
  
  September 09, 2024 11:31 ET (15:31 GMT)
Sep 6, 2024
- DJ Axsome Therapeutics Price Target Maintained With a $107.00/Share by Cantor Fitzgerald, from 10:23AM ET on Friday Sep 06, 2024 by Dow Jones
  10:23AM ET on Friday Sep 06, 2024 by Dow Jones
  Companies Mentioned: AXSM
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/AXSM/analyst-ratings
  
  (END) Dow Jones Newswires
  
  September 06, 2024 10:23 ET (14:23 GMT)

Sep 20, 2024
- DJ ADMA Biologics Price Target Maintained With a $20.00/Share by Cantor Fitzgerald, from 11:20AM ET on Friday Sep 20, 2024 by Dow Jones
  11:20AM ET on Friday Sep 20, 2024 by Dow Jones
  Companies Mentioned: ADMA
Sep 18, 2024
- DJ TG Therapeutics Price Target Maintained With a $49.00/Share by HC Wainwright & Co., from 1:12PM ET on Wednesday Sep 18, 2024 by Dow Jones
  1:12PM ET on Wednesday Sep 18, 2024 by Dow Jones
  Companies Mentioned: TGTX
- Sector Update: Health Care Stocks Steady Premarket Wednesday, from 9:14AM ET on Wednesday Sep 18, 2024 by MT Newswires
  9:14AM ET on Wednesday Sep 18, 2024 by MT Newswires
  Companies Mentioned: IBB, TGTX, XLV, ME, ROIV, OGN
- TG Therapeutics Reports 30-Minute BRIUMVI Infusions Well Tolerated in Relapsing Multiple Sclerosis Trial, from 8:25AM ET on Wednesday Sep 18, 2024 by MT Newswires
  8:25AM ET on Wednesday Sep 18, 2024 by MT Newswires
  Companies Mentioned: TGTX
- New BRIUMVI(R) (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis, from 7:15AM ET on Wednesday Sep 18, 2024 by Dow Jones
  7:15AM ET on Wednesday Sep 18, 2024 by Dow Jones
  Companies Mentioned: TGTX
- New Data for BRIUMVI(R) (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment, from 7:00AM ET on Wednesday Sep 18, 2024 by Dow Jones
  7:00AM ET on Wednesday Sep 18, 2024 by Dow Jones
  Companies Mentioned: TGTX
Sep 17, 2024
- ADMA Biologics to Join S&P SmallCap 600 Index, from 7:27AM ET on Tuesday Sep 17, 2024 by MT Newswires
  7:27AM ET on Tuesday Sep 17, 2024 by MT Newswires
  Companies Mentioned: ADMA
- ADMA Biologics Set to Join S&P SmallCap 600 Index, from 7:00AM ET on Tuesday Sep 17, 2024 by Dow Jones
  7:00AM ET on Tuesday Sep 17, 2024 by Dow Jones
  Companies Mentioned: ADMA
Sep 10, 2024
- ADMA Biologics to Participate in the 2024 Cantor Global Healthcare Conference, from 7:00AM ET on Tuesday Sep 10, 2024 by GlobeNewswire
  7:00AM ET on Tuesday Sep 10, 2024 by GlobeNewswire
  Companies Mentioned: ADMA
- ADMA Biologics to Participate in the 2024 Cantor Global Healthcare Conference, from 7:00AM ET on Tuesday Sep 10, 2024 by Dow Jones
  7:00AM ET on Tuesday Sep 10, 2024 by Dow Jones
  Companies Mentioned: ADMA

Axsome Therapeutics Inc
NASDAQ:AXSMUnited States

Search Criteria

Sep 20, 2024

DJ Axsome Therapeutics Price Target Maintained With a $107.00/Share by Cantor Fitzgerald, from 1:33PM ET on Friday Sep 20, 2024 by Dow Jones

Sep 16, 2024

DJ Axsome Therapeutics Price Target Maintained With a $107.00/Share by Cantor Fitzgerald, from 11:34AM ET on Monday Sep 16, 2024 by Dow Jones

Sep 12, 2024

Axsome Therapeutics Insider Sold Shares Worth $1,005,871, According to a Recent SEC Filing, from 3:14AM ET on Thursday Sep 12, 2024 by MT Newswires

Sep 9, 2024

DJ Axsome Therapeutics Price Target Maintained With a $107.00/Share by Cantor Fitzgerald, from 11:31AM ET on Monday Sep 09, 2024 by Dow Jones

Sep 6, 2024

DJ Axsome Therapeutics Price Target Maintained With a $107.00/Share by Cantor Fitzgerald, from 10:23AM ET on Friday Sep 06, 2024 by Dow Jones

Peers Headlines

Sep 20, 2024

DJ ADMA Biologics Price Target Maintained With a $20.00/Share by Cantor Fitzgerald, from 11:20AM ET on Friday Sep 20, 2024 by Dow Jones

Sep 18, 2024

DJ TG Therapeutics Price Target Maintained With a $49.00/Share by HC Wainwright & Co., from 1:12PM ET on Wednesday Sep 18, 2024 by Dow Jones

Sector Update: Health Care Stocks Steady Premarket Wednesday, from 9:14AM ET on Wednesday Sep 18, 2024 by MT Newswires

TG Therapeutics Reports 30-Minute BRIUMVI Infusions Well Tolerated in Relapsing Multiple Sclerosis Trial, from 8:25AM ET on Wednesday Sep 18, 2024 by MT Newswires

New BRIUMVI(R) (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis, from 7:15AM ET on Wednesday Sep 18, 2024 by Dow Jones

New Data for BRIUMVI(R) (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment, from 7:00AM ET on Wednesday Sep 18, 2024 by Dow Jones

Sep 17, 2024

ADMA Biologics to Join S&P SmallCap 600 Index, from 7:27AM ET on Tuesday Sep 17, 2024 by MT Newswires

ADMA Biologics Set to Join S&P SmallCap 600 Index, from 7:00AM ET on Tuesday Sep 17, 2024 by Dow Jones

Sep 10, 2024

ADMA Biologics to Participate in the 2024 Cantor Global Healthcare Conference, from 7:00AM ET on Tuesday Sep 10, 2024 by GlobeNewswire

ADMA Biologics to Participate in the 2024 Cantor Global Healthcare Conference, from 7:00AM ET on Tuesday Sep 10, 2024 by Dow Jones